SERVIER

About SERVIER

Founded to serve health, Servier is an international pharmaceutical group governed by a Foundation, which aspires to have a significant societal impact for patients and for a sustainable world. Its unique governance model allows it to fully serve its purpose with a long-term vision: to be committed to therapeutic progress for the benefit of patients. The 21,800 employees who make up the Group are committed to this common purpose, a source of daily inspiration. A world leader in cardiology, Servier aims to become a recognized, focused and innovative player in oncology by targeting difficult-to-treat cancers. This is why the Group dedicates more than 50% of its R&D budget to the development of targeted and innovative therapies in oncology. Neuroscience and immuno-inflammatory diseases are a future growth driver. In these areas, Servier focuses on a small number of specific pathologies where precise patient characterization allows for a targeted therapeutic response, thanks to precision medicine. To promote access to quality care for all, and at a lower cost, the Group also offers a range of generic drugs covering the majority of pathologies, building on strong brands in France, Eastern Europe, Brazil and Nigeria. In all these areas, the Group integrates the patient's voice at every stage of the drug lifecycle. Servier, headquartered in France, relies on a strong geographical presence in more than 150 countries and achieved a turnover of 4.7 billion euros in 2021.